Jason Johnson
Critical Care Medicine Orlando, FL Medical Doctor
NPI 1376833681 CMS profile 4049029
601 E Rollins St, Orlando, FL 32803
General payments
$202
Research payments
$4,410
Ownership & investment interest
$0
Through program year 2025, Jason Johnson of Orlando, FL is reported in the CMS Open Payments database as having received $202 across 10 general payments and $4,410 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 91st percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | Research | $4,410 | 1 | |
| 2024 | General | $83 | 3 | |
| 2023 | General | $27 | 1 | |
| 2022 | General | $19 | 2 | |
| 2021 | General | $39 | 2 | |
| 2019 | General | $34 | 2 |
Beside peers
- Jason Johnson
- Critical Care Medicine median
- Middle half of Critical Care Medicine
- National median
In program year 2025, general payments to Jason Johnson were reported at $0. Among 445 Critical Care Medicine profiles paid that year, the median was $97 and the middle half received between $33 and $255.
Show as a table
| Year | Jason Johnson | Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $34 | $103 | $29–$256 | $163 |
| 2020 | $0 | $60 | $22–$164 | $114 |
| 2021 | $39 | $115 | $30–$249 | $132 |
| 2022 | $19 | $97 | $27–$196 | $149 |
| 2023 | $27 | $104 | $31–$245 | $160 |
| 2024 | $83 | $93 | $28–$268 | $164 |
| 2025 | $0 | $97 | $33–$255 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 28 billing codesPaid by Medicare
$13,953
Medicare patients
74
Services billed
161
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 75% | |
| Atrial fibrillation | 66% | |
| Arthritis | 61% | |
| Heart failure | 59% | |
| Chronic kidney disease | 53% | |
| Diabetes | 49% | |
| COPD | 39% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
11 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Critical Care Medicine in Florida
Louis Guzzi
Critical Care Medicine · Orlando, FL
William Croley
Critical Care Medicine · Pensacola, FL
Gaston Cudemus Deseda
Critical Care Medicine · Naples, FL
David Becnel
Critical Care Medicine · Gainesville, FL
Gilles Chemtob
Critical Care Medicine · Clermont, FL
Nathan Waldron
Critical Care Medicine · Jacksonville, FL
Related records
Critical Care Medicine in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.